Participants and study design
idiopathic PD
This study design was a phase I, single-center, randomized, double-blinded, placebo-controlled trial, aiming to provide initial evidence of safety and tolerability for NR at a dose of 3000 mg daily. The trial was conducted at the Department of Neurology, Haukeland University Hospital, Norway, from the 29.04.22 to the 01.07.22. The first participant was enrolled on 29.04.22 and the last on 27.05.2022. Inclusion criteria were: (i) age equal to or greater than 35 years and lower than 100 years at time of enrollment, (ii) clinical diagnosis of idiopathic PD according to the MDS criteria